National trends of psychotropic medication use among patients diagnosed with anxiety disorders: Results from Medical Expenditure Panel Survey 2004-2009

Journal of Anxiety Disorders

Volumn 27, Issue 2, 2013, Pages 163-170

  Wu, Chung Hsuen ^a   Wang, Chi Chuan ^b,c   Katz, Aaron Jacob ^d   Farley, Joel ^d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b RTI HEALTH SOLUTIONS   (United States)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d University of North Carolina   (United States)

Author keywords

Antidepressants; Anxiety disorders; Benzodiazepines; Medical Expenditure Panel Survey (MEPS); National trends; Psychotropic medication use

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; AZAPIRONE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MIRTAZAPINE; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ANXIETY DISORDER; ARTICLE; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH STATUS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SELF REPORT; TREND STUDY;

ADULT; AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; FEMALE; HEALTH EXPENDITURES; HUMANS; INSURANCE COVERAGE; LOGISTIC MODELS; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS;

EID: 84874355652     PISSN: 08876185     EISSN: 18737897     Source Type: Journal    
DOI: 10.1016/j.janxdis.2012.11.004     Document Type: Article

References (46)

1. Agency for Healthcare Research and Quality (AHRQ) MEPS HC-089 2004 full year consolidated data file: Center for financing, access and cost trends 2006.
2. Agency for Healthcare Research and Quality (AHRQ) MEPS HC-097 2005 full year consolidated data file: Center for financing, access and cost trends 2007.
3. Agency for Healthcare Research and Quality (AHRQ) MEPS HC-105 2006 full year consolidated data file: Center for financing, access and cost trends 2008.
4. Agency for Healthcare Research and Quality (AHRQ) MEPS HC-113 2007 full year consolidated data file: Center for financing, access and cost trends 2009.
5. Agency for Healthcare Research and Quality (AHRQ) MEPS HC-121 2008 full year consolidated data file: Center for financing, access and cost trends 2010.
6. Agency for Healthcare Research and Quality (AHRQ) MEPS HC-126A 2009 prescribed medicines: Center for financing, access and cost trends 2011.
7. Agency for Healthcare Research and Quality (AHRQ) MEPS HC-128 2009 medical conditions: Center for financing, access and cost trends 2011.
8. Agency for Healthcare Research and Quality (AHRQ) MEPS HC-129 2009 full year consolidated data file: Center for financing, access and cost trends 2011.
9. American Psychiatric Association Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder, 2011 2004, Retrieved 2011, from:. http://www.psychiatryonline.com/pracGuide/PracticePDFs/ASD_PTSD_Inactivated_04-16-09.pdf.
10. American Psychiatric Association Treatment of patients with obsessive-compulsive disorder 2007, Retrieved 2011, from:. http://psychiatryonline.org/guidelines.aspx.
11. American Psychiatric Association Practice guideline for the treatment for patients with panic disorder 2009, Retrieved 2011, from:. http://www.psychiatryonline.com/pracGuide/PracticePDFs/PanicDisorder_2e_PracticeGuideline.pdf, 2nd edition.
12. Andersen R., Newman J.F. Societal and individual determinants of medical care utilization in the United States. Milbank Memorial Fund Quarterly Health and Society 1973, 51(1):95-100.
13. Andersen R.M. Revisiting the behavioral model and access to medical care: Does it matter?. Journal of Health and Social Behavior 1995, 36(1):1-10.
14. Andersen R.M. National health surveys and the behavioral model of health services use. Medical Care 2008, 46(7):647-650.
15. Anxiety Disorders Association of America (ADAA) Medications 2009, Retrieved December 2011, from:. http://www.adaa.org/sites/default/files/Medications%20Chart_updated%201209.pdf.
16. Bambauer K.Z., Sabin J.E., Soumerai S.B. The exclusion of benzodiazepine coverage in medicare: Simple steps for avoiding a public health crisis. Psychiatric Services 2005, 56(9):1143-1150.
17. Bereza B.G., Machado M., Einarson T.R. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clinical Therapeutics 2009, 31(6):1279-1280.
18. Chen H., Nwangwu A., Aparasu R., Essien E., Sun S., Lee K. The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatric Services 2008, 59(10):1191-1200.
19. Comer J.S., Mojtabai R., Olfson M. National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. American Journal of Psychiatry 2011, 168(10):1057-1060.
20. Davidson J.R. First-line pharmacotherapy approaches for generalized anxiety disorder. Journal of Clinical Psychiatry 2009, 70(Suppl. 2):25-30.
21. Devane C.L., Chiao E., Franklin M., Kruep E.J. Anxiety disorders in the 21st century: Status, challenges, opportunities, and comorbidity with depression. American Journal of Managed Care 2005, 11(12 Suppl.):S344-S353.
22. Ezzati-Rice T.M., Rohde F., Greenblatt J. Sample design of the medical expenditure panel survey household component, 1998-2007 2008, March, Methodology Report No. 22. http://www.meps.ahrq.gov/mepsweb/data_files/publications/mr22/mr22.pdf.
23. Karsnitz D.B., Ward S. Spectrum of anxiety disorders: Diagnosis and pharmacologic treatment. Journal of Midwifery and Women's Health 2011, 56(3):266-270.
24. Kessler R.C., Andrade L.H., Bijl R.V., Offord D.R., Demler O.V., Stein D.J. The effects of co-morbidity on the onset and persistence of generalized anxiety disorder in the ICPE surveys. International Consortium in Psychiatric Epidemiology. Psychological Medicine 2002, 32(7):1213-1220.
25. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005, 62(6):593-600.
26. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005, 62(6):617-620.
27. Lauderdale S.A., Sheikh J.I. Anxiety disorders in older adults. Clinics in Geriatric Medicine 2003, 19(4):721-730.
28. Leipzig R.M., Cumming R.G., Tinetti M.E. Drugs and falls in older people: A systematic review and meta-analysis: I. Psychotropic drugs. Journal of the American Geriatrics Society 1999, 47(1):30-40.
29. Madhusoodanan S., Bogunovic O.J. Safety of benzodiazepines in the geriatric population. Expert Opinion on Drug Safety 2004, 3(5):485-490.
30. Maglione M., Maher A.R., Hu J., Wang Z., Shanman R., Shekelle P.G., Perry T. Off-label use of atypical antipsychotics: An update. Comparative effectiveness reviews 2011, vol. 43. Agency for Healthcare Research and Quality, Rockville, MD. 02/12/2011.
31. Nutt D.J. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectrums 2005, 10(1):49-50.
32. Olfson M., Marcus S.C., Wan G.J., Geissler E.C. National trends in the outpatient treatment of anxiety disorders. Journal of Clinical Psychiatry 2004, 65(9):1166-1170.
33. Otte C. Incomplete remission in depression: Role of psychiatric and somatic comorbidity. Dialogues in Clinical Neuroscience 2008, 10(4):453-460. (Review).
34. Ravindran L.N., Stein M.B. The pharmacologic treatment of anxiety disorders: A review of progress. Journal of Clinical Psychiatry 2010, 71(7):839-840.
35. Revicki D.A., Travers K., Wyrwich K.W., Svedsater H., Locklear J., Mattera M.S., Montgomery S. Humanistic and economic burden of generalized anxiety disorder in North America and Europe. Journal of Affective Disorders 2011.
36. Roy-Byrne P.P., Davidson K.W., Kessler R.C., Asmundson G.J., Goodwin R.D., Kubzansky L., Stein M.B. Anxiety disorders and comorbid medical illness. General Hospital Psychiatry 2008, 30(3):208-210.
37. Ruscio A.M., Chiu W.T., Roy-Byrne P., Stang P.E., Stein D.J., Wittchen H.U., Kessler R.C. Broadening the definition of generalized anxiety disorder: Effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. Journal of Anxiety Disorders 2007, 21(5):662-670.
38. Sable J.A., Jeste D.V. Anxiety disorders in older adults. Current Psychiatry Reports 2001, 3(4):302-310.
39. Salzman C. The APA task force report on benzodiazepine dependence, toxicity, and abuse. American Journal of Psychiatry 1991, 148(2):151-160.
40. SAS Institute Inc SAS/STAT 9.2 User's Guide 2008, SAS Institute Inc, Cary, NC.
41. Smith R.P., Larkin G.L., Southwick S.M. Trends in U.S. emergency department visits for anxiety-related mental health conditions, 1992-2001. Journal of Clinical Psychiatry 2008, 69(2):286-290.
42. Strine T.W., Mokdad A.H., Balluz L.S., Gonzalez O., Crider R., Berry J.T., Kroenke K. Depression and anxiety in the United States: Findings from the 2006 behavioral risk factor surveillance system. Psychiatric Services 2008, 59(12):1383-1390.
43. Takkouche B., Montes-Martinez A., Gill S.S., Etminan M. Psychotropic medications and the risk of fracture: A meta-analysis. Drug Safety 2007, 30(2):171-180.
44. Todaro J.F., Shen B.J., Raffa S.D., Tilkemeier P.L., Niaura R. Prevalence of anxiety disorders in men and women with established coronary heart disease. Journal of Cardiopulmonary Rehabilitation and Prevention 2007, 27(2):86-90.
45. van Hout H.P., Beekman A.T., de Beurs E., Comijs H., van Marwijk H., de Haan M., Deeg D.J. Anxiety and the risk of death in older men and women. British Journal of Psychiatry 2004, 185:399-400.
46. Young A.S., Klap R., Sherbourne C.D., Wells K.B. The quality of care for depressive and anxiety disorders in the United States. Archives of General Psychiatry 2001, 58(1):55-60.